Xortx Therapeutics appoints Abigail Jenkins to board of directors

XORTX Therapeutics (XRTX) welcomes Abigail Jenkins to its Board of Directors. Abigail Jenkins, M.S., is the current President and CEO of Gamida Cell (GMDA) and a member of its Board of Directors. In connection with the appointment of Abigail Jenkins, XORTX has granted, in accordance with the Company’s stock option plan, 8,000 options to purchase common shares of the Company at an exercise price of $5.00 for a period of five years.